ピラルビシン
Based on 26 publication(s) in Google Scholar
Pirarubicin is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.14%
- CAS 番号: 72496-41-4
- 分子式: C32H37NO12
- 分子量:627.64
-
保管条件:
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Pirarubicin
More- J Control Release. 2026 May 10:393:114808. [Abstract]
- Int J Biol Macromol. 2024 Apr 10;267(Pt 2):131514. [Abstract]
- EMBO Mol Med. 2025 Nov 26. [Abstract]
- Nanoscale Horiz. 2025 Jun 23;10(7):1465-1477. [Abstract]
- Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
- J Mol Liq. 2023 Jun 12, 122324.
- Int J Pharm. 2022 May 25;620:121761. [Abstract]
- J Mol Liq. 2020, 114633.
- Cancer Drug Resist. 2020 Sep 4;3(4):947-958. [Abstract]
- Nanoscale. 2024 Nov 7;16(43):20131-20146. [Abstract]
- Int J Mol Sci. 2025 Oct 20;26(20):10189. [Abstract]
- Biomolecules. 2025 Jul 6;15(7):971. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Cancers (Basel). 2023 Apr 26;15(9):2487. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- iScience. 2026 Jan 27;29(2):114786. [Abstract]
- AAPS PharmSciTech. 2024 Sep 7;25(7):211. [Abstract]
- Heliyon. 2022 Jun 8;8(6):e09643. [Abstract]
- Mol Med Rep. 2024 May;29(5):84. [Abstract]
- Toxicol Appl Pharmacol. 2023 Mar 1:462:116411. [Abstract]
- Int J Hyperthermia. 2024 Feb 12;41(1):2316085. [Abstract]
- Genomics. 2022 Jan;114(1):125-137. [Abstract]
- Integr Cancer Ther. 2025 Jan-Dec:24:15347354251368410. [Abstract]
- Biol Methods Protoc. 2025 Feb 13;10(1):bpaf012. [Abstract]
- University of Paris. 2022 Sep 19.
- E3S Web of Conferences. 233, 02010 (2021).
Topoisomerase アイソフォーム固有の製品をすべて表示
MoreAntibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
|
Topoisomerase II |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L5178Y | IC50 |
2.3 x 10-8 M
Compound: Pirarubicin
|
Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability
Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability
|
[PMID: 31759851] |
Pirarubicin is a topoisomerase II inhibitor[1]. Pirarubicin shows inhibitory activities against M5076 and Ehrlich cells, with IC50s of 0.366 and 0.078 μM, respectively. The cytotoxicity of Pirarubicin toward M5076 cells is lower than toward Ehrlich cells, and this is due to the much lower expression of topoisomerase II in M5076 cells than in Ehrlich cells[2]. Pirarubicin (2.5, 5, 10 μg/mL) significantly induces autophagy in a dose dependent manner in bladder cancer (T24, EJ, 5637, J82 and UM-UC-3) cells. Furthmore, Pirarubicin (5 μg/mL) induces apoptosis through inhibition of mTOR/p70S6K/4E-BP1 in bladder cancer cells, and this effect is enhanced by inhibition of autophagy[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 72496-41-4
-
性状 Solid
-
分子量 627.64
-
分子式 C32H37NO12
-
Color Pink to red
-
SMILES
O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O
-
別名
THP; Pirarubicin
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer. [Abstract]2026 May 10:393:114808. PMID: 41839262 -
Int J Biol Macromol
Nucleus-targeting DNase I self-assembly delivery system guided by pirarubicin for programmed multi-drugs release and combined anticancer therapy. [Abstract]2024 Apr 10;267(Pt 2):131514. PMID: 38608986 -
EMBO Mol Med
Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]2025 Nov 26. PMID: 41299101 -
Nanoscale Horiz
pH-Triggered delivery of pirarubicin-gemcitabine duo using polymeric nanoparticles for synergistic breast cancer therapy. [Abstract]2025 Jun 23;10(7):1465-1477. PMID: 40396269 -
Int J Mol Med
Scutellarein regulates the PTEN/AKT/NFκB signaling pathway to reduce pirarubicin related liver inflammation. [Abstract]2023 Jul;52(1):55. PMID: 37232353 -
-
Int J Pharm
Development and evaluation of PLA based hybrid block copolymeric nanoparticles for systemic delivery of pirarubicin as an anti-cancer agent. [Abstract]2022 May 25;620:121761. PMID: 35472512 -
-
Cancer Drug Resist
Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells. [Abstract]2020 Sep 4;3(4):947-958. PMID: 35582217 -
Nanoscale
Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth in vivo. [Abstract]2024 Nov 7;16(43):20131-20146. PMID: 39420738 -
Int J Mol Sci
Atractylodes macrocephala Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis. [Abstract]2025 Oct 20;26(20):10189. PMID: 41155481 -
Biomolecules
Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives. [Abstract]2025 Jul 6;15(7):971. PMID: 40723843 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Cancers (Basel)
Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer. [Abstract]2023 Apr 26;15(9):2487. PMID: 37173953 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
iScience
Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth. [Abstract]2026 Jan 27;29(2):114786. PMID: 41704753 -
AAPS PharmSciTech
Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse. [Abstract]2024 Sep 7;25(7):211. PMID: 39242397 -
Heliyon
Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. [Abstract]2022 Jun 8;8(6):e09643. PMID: 35711974 -
Mol Med Rep
Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress. [Abstract]2024 May;29(5):84. PMID: 38516760 -
Toxicol Appl Pharmacol
Ring finger protein 10 improves pirarubicin-induced cardiac inflammation by regulating the AP-1/Meox2 signaling pathway. [Abstract]2023 Mar 1:462:116411. PMID: 36740146 -
Int J Hyperthermia
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model. [Abstract]2024 Feb 12;41(1):2316085. PMID: 38346911 -
Genomics
The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics. [Abstract]2022 Jan;114(1):125-137. PMID: 34843906 -
Integr Cancer Ther
Peach Gum Polysaccharide Prevents Chemotherapy-Induced Intestinal Injury and Degenerative Behavior. [Abstract]2025 Jan-Dec:24:15347354251368410. PMID: 40847988 -
Biol Methods Protoc
Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]2025 Feb 13;10(1):bpaf012. PMID: 40060949 -
-
溶剤 & 溶解度
DMSO : 10 mg/mL (15.93 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
プロトコル
MTS is used to analyze cell survival. Briefly, cells are plated in 96-well plates in triplicate at 2 × 103 cells per well and cultured in growth medium. Then cells are treated with pirarubicin at different concentrations (2.5 μg/mL, 5 μg/mL, 10 μg/mL) for 24 h. MTS reagent (5 mg/mL) is added and incubated at 37°C for 4 h. The absorbance is monitored at 490 nm using a microplate reader[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
An acute cardiac toxicity model is established by a single dose of 18 mg/kg pirarubicin through the caudal vein injection. Thirty-six rats are randomized equally to six groups: normal control, cardiac injury (THP) model, dexrazoxane (180 mg/kg), low-dose rutin (25 mg/kg), middle-dose rutin (50 mg/kg), and high-dose rutin (100 mg/kg). Rats in the rutin-treated group are administered different doses of rutin and CMC-Na for 7 days by gavage and a single dose of 18 mg/kg pirarubicin through caudal vein injection. Rats in the dexrazoxane-treated group receive sodium carboxymethylcellulose (CMC-Na) by gavage for six days. 40 mg/kg dexrazoxane is then administered to rats by intraperitoneal injection and 18 mg/kg pirarubicin is administered by caudal vein injection on day 7. Rats in the THP model group receive CMC-Na by gavage for seven days, followed by pirarubicin 18 mg/kg through the caudal vein injection on day 7. Rats in the normal control group receive CMC-Na by gavage for seven days, followed by saline through caudal vein injection on day 7[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Takigawa N, et al. Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines. Gan To Kagaku Ryoho. 1993 May;20(7):929-35. [Content Brief]
[2]. Nagai K, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol. 2002 Mar;49(3):244-50. Epub 2002 Jan 8. [Content Brief]
[3]. Li K, et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. Biochem Biophys Res Commun. 2015 May 1;460(2):380-5. [Content Brief]
[4]. Wang YD, et al. Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. J Asian Nat Prod Res. 2017 Oct 27:1-13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5933 mL | 7.9663 mL | 15.9327 mL | 39.8317 mL |
| 5 mM | 0.3187 mL | 1.5933 mL | 3.1865 mL | 7.9663 mL | |
| 10 mM | 0.1593 mL | 0.7966 mL | 1.5933 mL | 3.9832 mL | |
| 15 mM | 0.1062 mL | 0.5311 mL | 1.0622 mL | 2.6554 mL |
Powered by Bioz